Search

Johnson and Johnson

Закрыт

СекторЗдравоохранение

270.67 -1.65

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

266

Макс.

272.27

Ключевые показатели

By Trading Economics

Доход

299M

5.5B

Продажи

1.2B

25B

P/E

Средняя по отрасли

31.057

56.659

Прибыль на акцию

2.9

Дивидендная доходность

1.95

Рентабельность продаж

21.865

Сотрудники

138,200

EBITDA

721M

9B

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+3.85% upside

Дивиденды

By Acuity

Дивидендная доходность

Средняя по отрасли

1.95%

2.18%

Следующий отчет о доходах

13 окт. 2026 г.

Дата следующей выплаты дивидендов

8 сент. 2026 г.

Следующая эксдивидендная дата

24 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

22B

641B

Предыдущая цена открытия

272.32

Предыдущая цена закрытия

270.67

Новостные настроения

By Acuity

14%

86%

15 / 339 Рейтинг в Healthcare

Johnson and Johnson График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 сент. 2026 г., 00:01 UTC

Johnson & Johnson shares are higher in after-market trading, with no specific news driving the move. The stock reached a session high earlier today.

4 сент. 2026 г., 20:08 UTC

News

Shares of Johnson & Johnson are lower as Timothy Schmid exercised stock options for 33,597 shares valued at approximately $4.39 million.

3 сент. 2026 г., 23:41 UTC

News

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2 сент. 2026 г., 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

1 сент. 2026 г., 20:01 UTC

Johnson & Johnson shares are higher today, reaching the upper end of their one-month trading range during the session. No specific news was identified.

31 авг. 2026 г., 23:06 UTC

News

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

29 авг. 2026 г., 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

28 авг. 2026 г., 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

27 авг. 2026 г., 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

26 авг. 2026 г., 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

25 авг. 2026 г., 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

24 авг. 2026 г., 19:06 UTC

Social Media
News

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

21 авг. 2026 г., 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

20 авг. 2026 г., 23:41 UTC

News

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.

19 авг. 2026 г., 19:32 UTC

News
Social Media

Johnson & Johnson shares advance as EVP Jennifer Taubert exercises options for 15,000 shares valued at $2.38 million and receives regulatory clearance for MONARCH QUEST 3 software.

18 авг. 2026 г., 23:56 UTC

Social Media

Johnson & Johnson returns the C-CAR039 program to AbelZeta, while discussions about a potential acquisition of Legend Biotech continue. Shares are roughly flat in after-market trading.

17 авг. 2026 г., 23:06 UTC

Johnson & Johnson's shares are roughly flat in after-market trading. The stock remains positioned above its 20-day moving average and near its one-month range.

14 авг. 2026 г., 19:46 UTC

Johnson & Johnson shares are lower as pharmaceuticals sub-sector weakness persists. The stock reached a session low earlier before recovering slightly.

13 авг. 2026 г., 19:21 UTC

Johnson & Johnson shares are higher, reflecting broader market gains amid stabilizing inflation pressures and a drop in crude oil prices.

12 авг. 2026 г., 23:26 UTC

Johnson & Johnson shares are lower in after-market trading, despite initially rising above Wednesday's close. The stock remains above its 20-day moving average.

11 авг. 2026 г., 19:26 UTC

Johnson & Johnson shares are lower today, influenced by a downturn in the Pharmaceuticals sub-sector. The stock has shown notable volatility during the session.

10 авг. 2026 г., 23:06 UTC

News

Johnson & Johnson will present at the Morgan Stanley Healthcare Conference on September 14, 2026. Shares are roughly flat in after-market trading.

8 авг. 2026 г., 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

7 авг. 2026 г., 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

6 авг. 2026 г., 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

5 авг. 2026 г., 23:51 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

4 авг. 2026 г., 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

3 авг. 2026 г., 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

1 авг. 2026 г., 00:01 UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

31 июл. 2026 г., 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

Сравнение c конкурентами

Изменение цены

Johnson and Johnson Прогноз

Целевая цена

By TipRanks

3.85% рост

Прогноз на 12 месяцев

Средняя 285.82 USD  3.85%

Максимум 320 USD

Минимум 260 USD

Основано на мнении 17 аналитиков Wall Street, спрогнозировавших целевые цены для Johnson and Johnson  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

17 ratings

14

Покупка

3

Удержание

0

Продажа

Настроения

By Acuity

15 / 339Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat